Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 4730 common shares - Stock Titan

Arcutis Biotherapeutics (NASDAQ: ARQT) notice to sell 4730 common shares Stock Titan

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Attovia Therapeutics Appoints John W. Smither to Board of Directors

Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment

Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months